Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.43 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.42 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | NAMPT | P43490 | 1/20 | 0.39 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | RORC | P51449 | 1/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23274802 | 0.84 | MAPT (0.47) | USP2SMN1; SMN2KDM4EMAPTTHRB | |
| SCHEMBL255933 | 0.84 | DDB1 (0.43) | NR1H2DDB1CRBNUSP2SMN1; SMN2 | |
| SCHEMBL20564793 | 0.84 | DDB1 (0.43) | NR1H2DDB1CRBNUSP2SMN1; SMN2 | |
| SCHEMBL18897507 | 0.84 | DDB1 (0.43) | NR1H2DDB1CRBNUSP2SMN1; SMN2 | |
| SCHEMBL15740724 | 0.83 | NR1H2 (0.49) | NR1H2DDB1CRBNUSP2SMN1; SMN2 | |
| SCHEMBL1963747 | 0.81 | HPGD (0.44) | NR1H2DDB1CRBNUSP2SMN1; SMN2 | |
| SCHEMBL17081077 | 0.81 | NR1H2 (0.44) | NR1H2DDB1CRBNUSP2SMN1; SMN2 | |
| SCHEMBL21597812 | 0.81 | NR1H2 (0.44) | NR1H2DDB1CRBNUSP2SMN1; SMN2 | |
| SCHEMBL950867 | 0.81 | NR1H2 (0.44) | NR1H2DDB1CRBNUSP2SMN1; SMN2 | |
| SCHEMBL23580148 | 0.81 | NR1H2 (0.41) | NR1H2DDB1CRBNUSP2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024120471-A1 | COMPOUNDS TARGETING MUTANT OF P53 | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2024-06-13 | — | — | WO | disclosed |
| US-20220409593-A1 | PROGRANULIN MODULATORS AND METHODS OF USING THE SAME | ARKUDA THERAPEUTICS | 2022-12-29 | — | — | US | disclosed |
| EP-4048677-A1 | PROGRANULIN MODULATORS AND METHODS OF USING THE SAME | Arkuda Therapeutics (US) | 2022-08-31 | — | — | EP | disclosed |
| WO-2021081272-A1 | PROGRANULIN MODULATORS AND METHODS OF USING THE SAME | ARKUDA THERAPEUTICS (US) | 2021-04-29 | — | — | WO | disclosed |
| EP-3782997-A1 | FUSED PYRIMIDINE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF FIBROTIC DISEASES | Galapagos N.V. (BE) | 2021-02-24 | — | — | EP | disclosed |
| US-10093623-B2 | Cyclic amides as MetAP-2 inhibitors | MERCK PATENT GMBH (DE) | 2018-10-09 | — | — | US | disclosed |
| EP-2834221-B1 | CYCLIC AMIDES AS METAP-2 INHIBITORS | MERCK PATENT GMBH (DE) | 2016-05-25 | — | — | EP | disclosed |
| EP-2834221-B1 | CYCLIC AMIDES AS METAP-2 INHIBITORS | MERCK PATENT GMBH (DE) | 2016-05-25 | — | — | EP | disclosed |
| EP-2834221-A1 | CYCLIC AMIDES AS METAP-2 INHIBITORS | Merck Patent GmbH (DE) | 2015-02-11 | — | — | EP | disclosed |
| US-20150031670-A1 | CYCLIC AMIDES AS METAP-2 INHIBITORS | MERCK PATENT GMBH (DE) | 2015-01-29 | — | — | US | disclosed |
| US-20130196970-A1 | AMINO-PYRROLIDINE-AZETIDINE DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA, NV (BE) | 2013-08-01 | — | — | US | disclosed |
| US-20120101081-A1 | AMINO-PYRROLIDINE-AZETIDINE DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA, NV (BE) | 2012-04-26 | — | — | US | disclosed |
| US-20120101081-A1 | AMINO-PYRROLIDINE-AZETIDINE DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA, NV (BE) | 2012-04-26 | — | — | US | disclosed |
| WO-2012054721-A1 | AMINO-PYRROLIDINE-AZETIDINE DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICAL NV (BE) | 2012-04-26 | — | — | WO | disclosed |
| US-7868014-B2 | 1-(hetero)aryl-3-amino-pyrrolidine derivatives for use as mGluR3 antagonists | ELI LILLY AND COMPANY (US) | 2011-01-11 | — | — | US | disclosed |
| US-7638549-B2 | Kinesin spindle protein (KSP) inhibitors, e.g., 4-(2,5-Difluorophenyl)-N-[(3S,4S)-3-fluoropyrrolidin3-yl]-2-hydroxymethyl)-N-methyl-2-phenyl-2,5-dihydro-1N-pyrrole-1-carboxamide; antiproliferative and -carcinogenic agents | MERCK & CO. INC. (US) | 2009-12-29 | — | — | US | disclosed |
| EP-1805165-B1 | 1-(HETERO)ARYL-3-AMINO-PYRROLIDINE DERIVATIVES FOR USE AS MGLUR3 RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 2009-12-16 | — | — | EP | disclosed |
| US-20080300266-A1 | 1-(Hetero)Aryl-3-Amino-Pyrrolidine Derivatives for Use as Mglur3 Antagonists | ELI LILLY AND COMPANY (US) | 2008-12-04 | — | — | US | disclosed |
| EP-1805165-A1 | 1-(HETERO)ARYL-3-AMINO-PYROLLIDINE DERIVATIVES FOR USE AS MGLUR3 RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2007-07-11 | — | — | EP | disclosed |
| WO-2006044454-A1 | 1-(HETERO)ARYL-3-AMINO-PYROLLIDINE DERIVATIVES FOR USE AS MGLUR3 RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2006-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130196970-A1 | AMINO-PYRROLIDINE-AZETIDINE DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | PNLIP, LPL, MGLL | NR1H2 838/4885DDB1 2629/4885CRBN 3504/4885 |
| US-20120101081-A1 | AMINO-PYRROLIDINE-AZETIDINE DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | PNLIP, LPL, MGLL | NR1H2 838/4885DDB1 2629/4885CRBN 3504/4885 |
| US-10093623-B2 | Cyclic amides as MetAP-2 inhibitors | METAP2, METAP1, LNPEP | NR1H2 3040/4885DDB1 4142/4885CRBN 4018/4885 |
| US-20220409593-A1 | PROGRANULIN MODULATORS AND METHODS OF USING THE SAME | GRN, PSEN1, PSEN2 | NR1H2 3249/4885DDB1 2201/4885CRBN 1161/4885 |
| US-20080300266-A1 | 1-(Hetero)Aryl-3-Amino-Pyrrolidine Derivatives for Use as Mglur3 Antagonists | GRM3, GRM1, GRIA3 | NR1H2 590/4885DDB1 3881/4885CRBN 4647/4885 |
| US-20150031670-A1 | CYCLIC AMIDES AS METAP-2 INHIBITORS | METAP2, METAP1, ENPEP | NR1H2 3540/4885DDB1 4573/4885CRBN 4133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.